Access Bio, Inc.is a New Jersey based corporation formed in 2001 to develop, manufacture, and market in-vitro diagnostics tests worldwide. The Company utilizes advanced lateral flow technology for the production of point-of-care diagnostics to be sold to retail and the professional market. We have developed novel technologies for processing reagents and have produced these tests to meet FDA standards.
Access Bio plans to aggressively introduce other innovative rapid diagnostic products to the market. We focus on products which have significant market potential and high profit margin in the field of diagnostics (e.g., diabetes, cardiovascular disease, and neonatal diagnostics). A rapid gene chip product incorporating Peptide Nucleic Acid (PNA) technology, is being developed to detect specific genes or sequences associated with various disease indications. Proteomics technologies, which are not yet incorporated into any diagnostics products, are being used in our test development platform. There are currently no commercially available diagnostic products using proteomics technology. Our biochip line is presented as a rapid, one-step protein chip to detect multiple analytes and diagnose various diseases with a small volume of saliva, urine, serum, or whole blood. Assay results are converted to a digital signal off of the platform, which will enable quantitative results and communication of the test results between the point-of-test and medical experts through wireless or on-line technology. These products are used for both prognostic and diagnostic purposes.